| NCT06752876 | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) | WITHDRAWN | PHASE1 | 2027-12 | 2029-04 | 2029-04 |
| NCT06128044 | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | TERMINATED | PHASE1 | 2024-02-08 | 2025-05-30 | 2025-05-30 |
| NCT05722418 | CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | RECRUITING | PHASE1 | 2023-02-06 | 2027-12 | 2027-12 |
| NCT04637763 | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | RECRUITING | PHASE1 | 2021-05-26 | 2025-09 | 2025-08 |